生物瓣二尖瓣结构性毁损再换瓣的手术结局
该研究回顾了1990至2017年Cleveland Clinic 525例因生物瓣二尖瓣结构性毁损行再次换瓣的患者,其中孤立手术133例、合并其他手术392例。孤立再换瓣院内死亡仅1例(0.75%),合并手术组死亡28例(7.1%,P = .003),长期生存良好;合并手术组死亡风险因素包括心功能IV级、同期冠脉搭桥、体外循环时间延长和输血。
要点
- 孤立二尖瓣再换瓣治疗生物瓣结构性毁损手术风险极低(院内死亡0.75%)。
- 合并其他手术的再换瓣院内死亡7.1%,多为凝血病、血管麻痹和多器官衰竭。
- 合并手术组死亡风险因素:心功能IV级、同期CABG、体外循环延长、输血。
核心结论
- 生物瓣二尖瓣结构性毁损再换瓣手术风险低、长期生存良好。
- 孤立再换瓣手术风险接近零,合并手术风险较高。
研究设计与样本
- 回顾性队列研究,纳入1990年1月至2017年1月Cleveland Clinic 525例因生物瓣二尖瓣结构性毁损行再次换瓣的患者。
- 孤立手术133例(25%),合并其他手术392例(75%)。
主要发现
- 结构性毁损表现为生物瓣反流81%(425/525)、狭窄44%(231/525)。
- 孤立再换瓣院内死亡1例(0.75%)。
- 合并手术组院内死亡28例(7.1%,P = .003),其中19例(68%)死于凝血病、血管麻痹和多器官衰竭。
- 合并手术组时间相关死亡风险因素包括NYHA IV级症状、同期冠脉搭桥、体外循环时间延长和输血。
临床怎么用
- 对于生物瓣二尖瓣结构性毁损,孤立再换瓣手术风险极低,可作为治疗选择。
- 合并手术患者需关注心功能IV级、同期CABG、体外循环时间和输血等风险因素,优化手术方案和时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Reoperation for structural valve deterioration (SVD) of bioprosthetic mitral valves carries a presumed high operative risk, and transcatheter mitral valve-in-valve implantation has emerged as an alternative. However, surgical risk and long-term outcome following mitral valve re-replacement in these patients remain ill-defined. Hence, we sought to evaluate outcomes and long-term survival following surgical mitral valve re-replacement and to identify risk factors for mortality. METHODS: From January 1990 to January 2017, 525 patients underwent surgical mitral valve re-replacement at Cleveland Clinic for bioprosthetic SVD: 133 (25%) isolated operations and 392 (75%) with concomitant procedures. Surgical complications and modes of death were compiled, long-term mortality assessed, and risk factors identified using a multivariable nonproportional hazards model and random forest analysis. RESULTS: SVD was characterized by bioprosthetic regurgitation in 81% (425 out of 525) and stenosis in 44% (231 out of 525). One in-hospital death occurred after isolated valve re-replacement (0.75%) and 28 deaths occurred (7.1%; P = .003) after nonisolated re-replacement, 19 (68%) of which were from coagulopathy, vasoplegia, and multisystem organ failure. In the nonisolated group, incremental risk factors for time-related death after re-replacement included New York Heart Association functional class IV symptoms, concomitant coronary artery bypass grafting, prolonged cardiopulmonary bypass time, and transfusions. CONCLUSIONS: Mitral valve re-replacement for bioprosthetic SVD was associated with low surgical risk and excellent long-term survival. Isolated mitral valve re-replacement for bioprosthetic SVD had near-zero surgical risk. Excessive cardiopulmonary bypass duration and multiple transfusions correlated with increased early mortality in nonisolated procedures, as did preoperative severe heart failure. Optimal surgical plan and timing of surgery are keys to success.
引用
- Javadikasgari H, Chemtob RA, Gillinov AM, et al. Outcomes of mitral valve re-replacement for bioprosthetic structural valve deterioration. J Thorac Cardiovasc Surg. 2020. PMID: 33059934. doi:10.1016/j.jtcvs.2020.08.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。